types of glp 1 receptor agonists Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research GLP-1 Receptor Agonists as Treatments

GROWTH PLAYBOOK AND MARKET ENTRY Commercial Entry and Scaling Priorities Where to Play How to Win Distributor / Partner / Direct Entry Options Capability Thresholds Entry Risks and Mitigation 13

The presence of majority of the leading manufacturers, such as Novo Nordisk, Eli Lilly, and AstraZeneca, has also boosted drug availability and clinical research activities in the region

The neuroprotective effect of GLP-1RAs through GABAergic modulation not only supports its clinical potential in neurodegenerative diseases such as AD, HD, and Parkinsons diseases (PD), but also adds to our fundamental understanding of GLP-1s pleiotropic molecular network with a special focus on its ocular therapeutic potential

Medications like cyclosporine, tacrolimus, azathioprine, or high-dose corticosteroids reduce the immune surveillance that keeps probiotic bacteria safely contained within the intestinal tract